A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)
Public ClinicalTrials.gov record NCT02139943. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the effects of administration of canagliflozin 100 mg and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of Type 1 Diabetes Mellitus (T1DM).
Study identification
- NCT ID
- NCT02139943
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 352 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 25 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2014
- Primary completion
- May 31, 2015
- Completion
- May 31, 2015
- Last update posted
- Jul 17, 2016
2014 – 2015
United States locations
- U.S. sites
- 46
- U.S. states
- 23
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Concord | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Los Gatos | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Temecula | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Ventura | California | — | — |
| Not listed | Walnut Creek | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Council Bluffs | Iowa | — | — |
| Not listed | Des Moines | Iowa | — | — |
| Not listed | Baton Rouge | Louisiana | — | — |
| Not listed | Rockville | Maryland | — | — |
| Not listed | Billings | Montana | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | El Paso | Nevada | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Nashua | New Hampshire | — | — |
| Not listed | Billings | New York | — | — |
| Not listed | Smithtown | New York | — | — |
| Not listed | Morehead City | North Carolina | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Mentor | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Greer | South Carolina | — | — |
| Not listed | Bloomington | Tennessee | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | El Paso | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Schertz | Texas | — | — |
| Not listed | Tomball | Texas | — | — |
| Not listed | Ogden | Utah | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02139943, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 17, 2016 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02139943 live on ClinicalTrials.gov.